Institution
Pharmaceutical Product Development
Company•Wilmington, North Carolina, United States•
About: Pharmaceutical Product Development is a company organization based out in Wilmington, North Carolina, United States. It is known for research contribution in the topics: Immunotoxin & Fusion protein. The organization has 402 authors who have published 353 publications receiving 16396 citations.
Topics: Immunotoxin, Fusion protein, Population, Cancer, Antigen
Papers published on a yearly basis
Papers
More filters
TL;DR: The results reveal the therapeutic potential of CD64-immunotoxin treatment in cutaneous leishmaniasis, but also challenge the clinical relevance of Th1 boosting, as suggested in established murine models, for therapeutic and vaccination strategies in human leish maniasis.
3 citations
TL;DR: In this article, a machine learning model is proposed to process the line notation of small organic molecules, allowing the prediction of their melting points, and the model prediction accuracy benefits from training upon different canonicalized SMILES forms of the same molecules.
3 citations
TL;DR: Current participation and ethnic diversity in clinical trials is evaluated using data from Ipsos’ Tandem Oncology Monitor, a robust, nationwide system that collects actual prescriptions and clinical trial participation by indication from 500 oncologists and hematologists from the United States.
Abstract: e17586 Background: According to the National Cancer Institute (NCI), approximately 3 percent of adult cancer patients participate in clinical trials despite the NCCN guidelines frequently recommend...
3 citations
29 Apr 2019
TL;DR: Ward Clinical pharmacy, pharmaceutical care, and consultant pharmacist service can be considered interesting instruments in the world of cognitive service to improve global clinical/ economical results in multi-disciplinary medical team.
Abstract: Ward Clinical pharmacy, pharmaceutical care, and consultant
pharmacist service can be considered interesting instruments in the
world of cognitive service to improve global clinical/ economical
results in multi-disciplinary medical team.
3 citations
TL;DR: The results obtained from this study showed that the bag's material of construction and the drugs formulation did not impact the mass of the leachables administered, but for shorter contact durations, refrigerated storage, and higher molecular weight compounds, the patient would be exposed to a majority of theLeachables originating from the vial.
3 citations
Authors
Showing all 403 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Liangbing Hu | 128 | 480 | 61244 |
| Evan A. Stein | 80 | 340 | 36392 |
| Steven J. Schwartz | 75 | 313 | 17613 |
| Debra A. Schaumberg | 62 | 154 | 15505 |
| Lynda A. Szczech | 58 | 175 | 13972 |
| Kim L. R. Brouwer | 57 | 247 | 12521 |
| Robert S. Wallis | 57 | 147 | 10420 |
| Marina A. Dobrovolskaia | 43 | 122 | 10915 |
| Al Artaman | 38 | 41 | 61792 |
| Bindu Kalesan | 38 | 123 | 8523 |
| Stefan Barth | 34 | 238 | 4509 |
| Yu.N. Makarov | 32 | 214 | 3578 |
| Earl Hubbell | 28 | 76 | 12553 |
| Alex Aravanis | 27 | 74 | 5230 |
| Izabela Konczak | 24 | 47 | 1770 |